Jetske M. Meerum Terwogt

Author

Also Known As

J M M Terwogt, J M Meerum Terwogt, J. M. Meerum Terwogt, J.M. Meerum Terwogt, Jetske M Meerum Terwogt, Jetske M. Meerum Terwogt, Jetske M.Meerum Terwogt, Jetske Meerum Terwogt

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Slotervaartziekenhuis Leiden University Medical Center University Medical Center Utrecht

About

Jetske M. Meerum Terwogt is an author at The Netherlands Cancer Institute specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	956
2	Engineering	1	1	33
3	Health Sciences	1	1	50
4	Chemical Engineering	1	1	33
5	Chemistry	1	1	33

Jetske M. Meerum Terwogt

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial Hanna van Waart, Martijn M. Stuiver, Wim H. van Harten, Journal of Clinical Oncology	2015	635
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken, The Lancet Oncology Surgical OncologyChemotherapy Versus ChemoradiotherapyGastrointestinal OncologyResectable Gastric CancerMedicine	2018	562
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel Jetske M. Meerum Terwogt, W.W. ten Bokkel Huinink, Jan H.M. Schellens, Anti-Cancer Drugs	2001	276
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer, The Lancet Oncology MedicineClinical TrialsGynecologyBreast CancerAromatase	2017	157
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin Jetske M. Meerum Terwogt, Gerard Groenewegen, Dick Pluim, Cancer Chemotherapy and Pharmacology Lipid PreparationPharmaceutical SciencePharmacokinetic StudyPharmacologyRadiation Oncology	2002	122
Phase I and Pharmacokinetic Study of Oral Paclitaxel Mirte M. Malingré, Jetske M. Meerum Terwogt, Jos H. Beijnen, Journal of Clinical Oncology	2000	99
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – A phase II trial D.B.Y. Fontein, Ayoub Charehbili, J.W.R. Nortier, European Journal of Cancer Endocrine OncologyBreast OncologyOncologyPhase Ii TrialGynecology	2014	85
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer Jetske M. Meerum Terwogt, I A M Mandjes, H. Sindermann, British Journal of Cancer	1999	63
Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer Hanna van Waart, Martijn M. Stuiver, Wim H. van Harten, International Journal of Colorectal Disease Physical ActivityGastrointestinal OncologyExerciseMedicineExercise Physiology	2017	50
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients Joseph Gligorov, Beyhan Ataseven, Mark Verrill, European Journal of Cancer Breast OncologyMedicinePrimary AnalysisAdjuvant TreatmentBreast Cancer	2017	46

Page 1